Any new ATTR-CM stabiliser is judged against tafamidis's NICE TA984 QALY model, while 15,000 to 36,000 UK patients remain undiagnosed.

Tafamidis (Vyndaqel 61mg, Pfizer) is NHS England's commissioned ATTR-CM standard via NICE's standard Technology Appraisal route, now updated as TA984 (June 2024), with an estimated 40-50% PAS bringing its effective NHS price to roughly £12,000-18,000 a year. Uptake has grown fast since 2023 commissioning, 3,000-4,000 patients today, adding 1,500-2,000 a year, but that growth is diagnosis-limited, not treatment-limited: true UK ATTRwt-CM prevalence is estimated at 20,000-40,000, meaning 15,000-36,000 patients remain undiagnosed. Acoramidis (Beyonttra in the UK, Bayer), MHRA-approved in late April 2025, received a positive NICE recommendation under TA1121 in January 2026, setting the second CM-stabiliser comparator bar.

No single NICE-commissioned UK drug currently covers both cardiomyopathy and polyneuropathy, even though some ATTR patients present with mixed phenotype, a genuine dual-indication white space. The harder near-term reality for any new CM stabiliser is the NICE comparator: a new entrant must show superiority in QALY terms or equivalence at a lower effective NHS price against both tafamidis and acoramidis. The National Amyloidosis Centre, led by Professor Hawkins at UCL and Royal Free, is NICE's appointed clinical expert for every ATTR appraisal to date, and its surveillance registry of 400-500 monitored patients is the deepest UK evidence base available to any pre-launch sponsor.

The National Amyloidosis Centre's clinical testimony shapes every NICE ATTR outcome to date.

Five questions this report answers:

Q1 - What clinical or economic case must a new ATTR-CM stabiliser make against tafamidis and acoramidis?

Q2 - How large is the diagnosed and undiagnosed UK ATTR population before launch?

Q3 - What role does the National Amyloidosis Centre play in a NICE ATTR appraisal?

Q4 - What deliverable formats come with a commissioned UK ATTR launch readiness assessment?

Q5 - What must a pre-launch ATTR amyloidosis asset prove to succeed in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#ATTRAmyloidosis #NICE #UKMarketAccess #RareDisease #Cardiology #LaunchReadiness

Live report page:  https://axlrx.ai/attr-amyloidosis/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/